MobilEye Global Inc vs uniQure N.V. Ordinary Shares — how do they compare? MobilEye Global Inc trades at $7.1 (market cap $5.97B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: MobilEye Global Inc is far larger — about 4× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MBLY | QURE | |
|---|---|---|
Market Cap | $5.97B | $1.48B |
Volume | 6,124,531 | 2,488,780 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.33 | $70.59 |
52-Week Low | $6.56 | $9.03 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $4.53B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.02, up 2.63% with recent earnings beats but faces bearish technical signals and significant net losses. The stock shows strong institutional support with 57.7% analyst buy ratings and a $10.77 consensus target, yet profitability remains challenged with a -201.5% net margin. Recent news highlights ADAS business momentum and autonomous vehicle expansion opportunities.
The outlook presents a high-risk opportunity with potential upside from autonomous driving adoption, but investors face substantial execution risks and ongoing losses. Key catalysts include Porsche launch progress and robotaxi developments, while competitive pressures and cash flow volatility remain significant concerns for near-term performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →